IRIS Archives

Information and Referral and Internet Sightings

IRIS@LISTSERV.ICORS.ORG
Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
news byte: FDA Conditionally Approves Risperdal for Children
From:
Sylvia Caras <[log in to unmask]>
Reply To:
[log in to unmask]
Date:
Mon, 25 Jun 2007 10:31:27 -0700
Content-Type:
text/plain
Parts/Attachments:
text/plain (9 lines) 
Johnson & Johnson on Thursday said U.S. regulators have given 
conditional approval for use of its drug Risperdal as a treatment for 
adolescents with schizophrenia and children and adolescents in the 
manic phase of bipolar disorder.



Powered by LSoft's LISTSERV(R) list management software

ATOM RSS1 RSS2